Pragmatic Trial

What makes a trial “pragmatic”

A pragmatic trial is a randomized controlled trial designed to answer a real-world, practical question — does this intervention work when delivered under the conditions clinicians and health systems actually operate in — rather than the narrower question of whether it works under ideal, tightly controlled conditions. It is still an experimental design: participants are still randomly allocated between the intervention and a comparator, which is what distinguishes it from a purely observational real-world study. What changes, relative to a conventional explanatory trial, is a cluster of protocol decisions around that randomization: who is eligible, where and by whom the intervention is delivered, how strictly the protocol is followed, what the comparator is, and what outcomes are measured.

The term sits opposite explanatory trial in a paired vocabulary that research administrators, IRBs/RECs, and funders use to describe trial intent. Neither term is a formal regulatory category the way Randomized Controlled Trial (RCT) or clinical trial phase are — they describe design orientation, not a phase or a regulatory classification, and a single trial can be pragmatic on some design dimensions and explanatory on others.

The pragmatic-explanatory continuum, not a binary label

Very few trials are purely one or the other. A foundational methodological point — formalized by the original PRECIS tool and its successor, PRECIS-2 — is that pragmatism is best understood as a continuum across several independent design domains, not a single yes/no classification for the trial as a whole. A trial can be highly pragmatic in its eligibility criteria (enrolling almost anyone who would realistically receive the intervention) while remaining explanatory in its primary outcome (a lab biomarker rather than a clinical endpoint measured in routine records).

PRECIS-2: the standard framework

PRECIS-2 (PRagmatic-Explanatory Continuum Indicator Summary-2), published by Loudon and colleagues in 2015 as a revision of the original PRECIS tool, is the widely adopted instrument for locating a trial’s design along the pragmatic-explanatory spectrum. It scores a trial across nine design domains, each rated on a 1 (very explanatory) to 5 (very pragmatic) scale:

• Eligibility criteria — how broadly or narrowly the trial defines who can enroll.
• Recruitment — how participants are identified and invited (e.g., routine clinical contact vs. dedicated study advertising).
• Setting — whether the trial runs in the same settings where the intervention would ordinarily be delivered.
• Organisation — whether the intervention is delivered using the resources and expertise normally available, or extra study-specific infrastructure.
• Flexibility: delivery — how much latitude those delivering the intervention have to adapt it, as they would in usual practice.
• Flexibility: adherence — how much latitude participants have in how closely they follow the intervention.
• Follow-up — how closely the intensity and schedule of follow-up matches usual care versus study-driven monitoring.
• Primary outcome — whether the outcome measured is directly relevant to participants and decision-makers, or a surrogate/mechanistic measure.
• Primary analysis — whether the analysis includes all participants as they were managed in practice (e.g., intention-to-treat) or is restricted to isolate an idealized effect.

Plotting the nine scores produces a “wheel” diagram: a trial with scores clustered near the center is more explanatory; one with scores near the outer edge is more pragmatic. Research teams typically apply PRECIS-2 during protocol design, as a structured way to check that specific design choices actually match the trial’s stated purpose, rather than only after the fact.

Why the distinction matters for research administration

The pragmatic/explanatory orientation has practical downstream consequences a research office will encounter directly: pragmatic trials more often use routinely collected data (electronic health records, claims, registries) rather than dedicated case report forms, which raises different data-governance and informed consent considerations (some pragmatic and cluster-randomized designs use waived or modified consent models where individual-level, protocol-driven consent would be impractical); broad eligibility and usual-care delivery affect IRB/REC risk assessment differently than a tightly controlled explanatory protocol; and pragmatic trial results are what payers, guideline bodies, and health systems tend to weight most heavily for real-world adoption decisions, since they are designed to answer “will this work as actually deployed,” not only “can this work under ideal conditions.” Funders increasingly specify pragmatic design elements explicitly in trial-focused funding calls for comparative-effectiveness and implementation research.

Pragmatic trial vs. real-world evidence vs. non-interventional study

These three terms are frequently used loosely as synonyms in practice, but they describe distinct things: a pragmatic trial is a randomized, interventional design placed toward the pragmatic end of the PRECIS-2 continuum; Real-World Evidence (RWE) is evidence about intervention use and outcomes derived from real-world data sources (which can come from a pragmatic trial, a registry, or claims data, among others); and a Non-Interventional Study involves no random assignment at all — treatment is determined by usual clinical decision-making, not a study protocol. A pragmatic trial randomizes; a non-interventional study does not. Both can generate real-world evidence, but only one is a trial.

Related CASRAI terms

• Randomized Controlled Trial (RCT) — the base experimental design that pragmatic and explanatory trials are both variants of.
• Research Study Types — the broader observational-vs-experimental classification this term sits within.
• Real-World Evidence (RWE) — evidence derived from real-world data sources, which a pragmatic trial can generate.
• Non-Interventional Study — the non-randomized counterpart, distinguished from a pragmatic trial by the absence of random assignment.
• Clinical Trial Phases and What Is a Clinical Trial? (NIH Definition) — related trial-classification reference pages.
• Informed Consent — relevant to the modified consent models some pragmatic designs use.
• Clinical Research — this term’s cluster hub.

References

• Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. “The PRECIS-2 tool: designing trials that are fit for purpose.” BMJ, 2015;350:h2147.
• Ford I, Norrie J. “Pragmatic Trials.” New England Journal of Medicine, 2016;375:454-463.
• Thorpe KE et al. “A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.” Journal of Clinical Epidemiology, 2009;62(5):464-475 (the original PRECIS tool that PRECIS-2 revised).

Frequently Asked Questions

What is a pragmatic trial?

A pragmatic trial is a randomized controlled trial designed to test whether an intervention works under the real-world conditions clinicians and health systems actually operate in, rather than under the tightly controlled conditions of a conventional explanatory trial. It still randomly allocates participants between the intervention and a comparator — what changes is a cluster of protocol choices around eligibility, setting, delivery, and outcomes.

What is the difference between a pragmatic trial and an explanatory trial?

The two terms describe opposite ends of a design continuum, not a strict either/or split. A pragmatic trial favors broad eligibility criteria, delivery in usual-care settings, flexible protocols, and outcomes that matter to patients and decision-makers, while an explanatory trial favors narrower eligibility, tightly controlled delivery, and surrogate or mechanistic outcomes. Most trials sit somewhere between the two extremes rather than being purely one or the other.

Is a pragmatic trial the same as a randomized controlled trial (RCT)?

A pragmatic trial is a type of Randomized Controlled Trial (RCT), not a separate category from it. “Pragmatic” and “explanatory” describe where a trial’s design sits on a continuum — broad or narrow eligibility, usual-care or controlled delivery, and so on — while randomization itself is the feature both pragmatic and explanatory trials share as RCTs.

What is PRECIS-2?

PRECIS-2 (PRagmatic-Explanatory Continuum Indicator Summary-2) is the standard framework for locating a trial’s design along the pragmatic-explanatory continuum. It scores a trial across nine design domains — including eligibility criteria, setting, flexibility of delivery, and primary outcome — each rated from 1 (very explanatory) to 5 (very pragmatic), rather than assigning the trial a single pragmatic-or-explanatory label.

Is a pragmatic trial the same as real-world evidence?

No. A pragmatic trial is a randomized, interventional design placed toward the pragmatic end of the PRECIS-2 continuum, while Real-World Evidence (RWE) is evidence derived from real-world data sources more broadly, which can come from a pragmatic trial, a registry, or claims data. A pragmatic trial can generate real-world evidence, but not all real-world evidence comes from a randomized trial.